InspireMD Announces First Quarter 2020 Financial Results
May 12, 2020 07:00 ET
|
InspireMD, Inc.
First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets Management to host investor conference call today,...
InspireMD to Report First Quarter 2020 Financial Results and Provide Business Update on Tuesday, May 12
May 05, 2020 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
InspireMD Announces Fourth Quarter and Year-End 2019 Financial Results
March 10, 2020 08:00 ET
|
InspireMD, Inc.
Robust CGuard™ EPS year-over-year revenue growth of 31% Management to host investor conference call today, March 10, at 8:30am ET TEL AVIV, Israel, March 10, 2020 (GLOBE NEWSWIRE) -- InspireMD,...
InspireMD to Report Fourth Quarter 2019 Financial Results and Provide Business Update on Tuesday, March 10
March 03, 2020 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
InspireMD Announces Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2020
January 29, 2020 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Jan. 29, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmission at LINC, 28th to the 31st January 2020, in Leipzig, Germany
January 27, 2020 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Jan. 27, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Announces Strong Preliminary Fourth Quarter 2019 Revenue and Reports Inducement Award Under NYSE American Company Guide §711(a)
January 06, 2020 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, Jan. 06, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...
InspireMD Announces Planned Leadership Transition
December 10, 2019 08:00 ET
|
InspireMD, Inc.
Life sciences industry veteran Marvin Slosman appointed Chief Executive Officer Appointment adds significant medical technology commercialization experience to the InspireMD team TEL AVIV, Israel,...
InspireMD Reports Updated Positive CGuard™ EPS Data Presented at VEITH 2019
November 26, 2019 08:00 ET
|
InspireMD, Inc.
CGuard™ EPS clinical data featured as a prominent discussion point in multiple key presentations Data from investigator-initiated multicenter, 729-patient IRONGUARD 2 study suggests that the use...
UPDATE: InspireMD Announces Third Quarter 2019 Financial Results
November 12, 2019 08:58 ET
|
InspireMD, Inc.
Strong revenue driven by record orders of CGuard™ EPS Management to host investor conference call today, November 12, at 8:30am ET TEL AVIV, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- InspireMD,...